RU2640256C2 - Средства и способы предсказания ответа на лечение гепатита b - Google Patents

Средства и способы предсказания ответа на лечение гепатита b Download PDF

Info

Publication number
RU2640256C2
RU2640256C2 RU2014142009A RU2014142009A RU2640256C2 RU 2640256 C2 RU2640256 C2 RU 2640256C2 RU 2014142009 A RU2014142009 A RU 2014142009A RU 2014142009 A RU2014142009 A RU 2014142009A RU 2640256 C2 RU2640256 C2 RU 2640256C2
Authority
RU
Russia
Prior art keywords
hepatitis
treatment
carnitine
patient
hbv
Prior art date
Application number
RU2014142009A
Other languages
English (en)
Russian (ru)
Other versions
RU2014142009A (ru
Inventor
Хендрик Виллем РЕСИНК
Лауис ЯНСЕН
Нелте Акке КОТСТРА
Original Assignee
Академис Медис Сентрум
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Академис Медис Сентрум filed Critical Академис Медис Сентрум
Publication of RU2014142009A publication Critical patent/RU2014142009A/ru
Application granted granted Critical
Publication of RU2640256C2 publication Critical patent/RU2640256C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/131—Allele specific probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2014142009A 2012-03-19 2013-03-19 Средства и способы предсказания ответа на лечение гепатита b RU2640256C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12160199.1 2012-03-19
EP12160199 2012-03-19
EP12186188 2012-09-26
EP12186188.4 2012-09-26
PCT/NL2013/050204 WO2013141705A2 (en) 2012-03-19 2013-03-19 Means and methods for response prediction of hepatitis b treatment

Publications (2)

Publication Number Publication Date
RU2014142009A RU2014142009A (ru) 2016-05-10
RU2640256C2 true RU2640256C2 (ru) 2017-12-27

Family

ID=47997743

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014142009A RU2640256C2 (ru) 2012-03-19 2013-03-19 Средства и способы предсказания ответа на лечение гепатита b

Country Status (9)

Country Link
US (2) US20150044167A1 (enExample)
EP (1) EP2828401B1 (enExample)
BR (1) BR112014023296A2 (enExample)
ES (1) ES2657266T3 (enExample)
HK (1) HK1206791A1 (enExample)
IN (1) IN2014MN01989A (enExample)
MX (1) MX2014011256A (enExample)
RU (1) RU2640256C2 (enExample)
WO (1) WO2013141705A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105829548A (zh) * 2013-12-17 2016-08-03 豪夫迈·罗氏有限公司 用于hbv治疗反应的生物标记物
EP3322820A1 (en) * 2015-07-15 2018-05-23 H. Hoffnabb-La Roche Ag Biomarkers for hbv treatment response
CN109504763B (zh) * 2018-12-17 2020-09-04 北京三元基因药业股份有限公司 用于预测α干扰素治疗乙肝患者疗效的分子标记
UA129589C2 (uk) 2018-12-19 2025-06-11 Лео Фарма А/С Аніліди амінокислот як низькомолекулярні модулятори il-17
CN115267193B (zh) * 2022-09-20 2022-12-27 北京大学 用于判断生物样本中HBsAg来源的方法及系统和用途

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ERIK H. C. J. BUSTER et al. Factors That Predict Response of Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B to Peginterferon-Alfa, GASTROENTEROLOGY, 2009, Vol.137, pp. 2002-2009. *
LIFENG LIU et al. Effects of Variant rs346473 in ARHGAP24 Gene on Disease Progression of HBV Infection in Han Chinese Population, J Huazhong Univ Sci Technol ［ Med Sci ］ , 2011, Vol. 31, No.4, pp. 482-487. *
LIFENG LIU et al. Effects of Variant rs346473 in ARHGAP24 Gene on Disease Progression of HBV Infection in Han Chinese Population, J Huazhong Univ Sci Technol ［ Med Sci ］ , 2011, Vol. 31, No.4, pp. 482-487. MILAN J. SONNEVELD et al. Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B, GASTROENTEROLOGY, 2012, Vol.142, pp. 513-520. MELANIE KOLZ et al. Meta-Analysis of 28,141 Individuals Identifies Common Variants within Five New Loci That Influence Uric Acid Concentrations, PLoS Genetics, June 2009, Volume 5, Issue 6, e1000504. ERIK H. C. J. BUSTER et al. Factors That Predict Response of Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B to Peginterferon-Alfa, GASTROENTEROLOGY, 2009, Vol.137, pp. 2002-2009. M. BRION et al. New technologies in the genetic approach to sudden cardiac death in the young, Forensic Science International, 2010, Vol.203, pp. 15-24. Т.В. СИМАНКОВА и др. Полиморфизм гена ИЛ-28В как преди *
M. BRION et al. New technologies in the genetic approach to sudden cardiac death in the young, Forensic Science International, 2010, Vol.203, pp. 15-24. *
MELANIE KOLZ et al. Meta-Analysis of 28,141 Individuals Identifies Common Variants within Five New Loci That Influence Uric Acid Concentrations, PLoS Genetics, June 2009, Volume 5, Issue 6, e1000504. *
MILAN J. SONNEVELD et al. Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B, GASTROENTEROLOGY, 2012, Vol.142, pp. 513-520. *
Т.В. СИМАНКОВА и др. Полиморфизм гена ИЛ-28В как предиктор ответа на противовирусную терапию хронического гепатита С, Клиническая фармакалогия и терапия. 2012, т. 21, No. 1, с. 1-6. *

Also Published As

Publication number Publication date
HK1206791A1 (en) 2016-01-15
MX2014011256A (es) 2015-07-14
US20150044167A1 (en) 2015-02-12
IN2014MN01989A (enExample) 2015-07-10
WO2013141705A3 (en) 2013-12-05
BR112014023296A2 (pt) 2019-09-24
US20180044735A1 (en) 2018-02-15
RU2014142009A (ru) 2016-05-10
ES2657266T3 (es) 2018-03-02
EP2828401A2 (en) 2015-01-28
EP2828401B1 (en) 2017-10-25
WO2013141705A2 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
Halgand et al. Hepatitis B virus pregenomic RNA in hepatocellular carcinoma: a nosological and prognostic determinant
Nishijima et al. Dynamics of hepatitis B virus quasispecies in association with nucleos (t) ide analogue treatment determined by ultra-deep sequencing
US20180044735A1 (en) Method of treating hepatitis b
US20220202770A1 (en) Composition for treating hepatitis b, and method for evaluating replication activity of hepatitis b virus
CN101812537B (zh) 同时检测乙型肝炎病毒三种核苷酸类似物耐药位点的方法及其试剂盒
CN115066505A (zh) 生物标记物及其在治疗慢性乙型肝炎感染中的用途
Khattab et al. Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy
Bayliss et al. Advances in the molecular diagnosis of hepatitis B infection: providing insight into the next generation of disease
Hao et al. Naturally occurring deletion/insertion mutations within HBV whole genome sequences in HBeAg-positive chronic hepatitis B patients are correlated with baseline serum HBsAg and HBeAg levels and might predict a shorter interval to HBeAg loss and seroconversion during antiviral treatment
Wang et al. Integrating nested PCR with high-throughput sequencing to characterize mutations of HBV genome in low viral load samples
Ringlander et al. Deep sequencing of hepatitis B virus using Ion Torrent fusion primer method
Widasari et al. A deep-sequencing method detects drug-resistant mutations in the hepatitis B virus in Indonesians
Wang et al. Viral quasispecies of hepatitis B virus in patients with YMDD mutation and lamivudine resistance may not predict the efficacy of lamivudine/adefovir rescue therapy
Roque-Afonso et al. Monitoring the Emergence of Hepatitis B Virus Polymerase Gene Variants during Lamivudine Therapy in Human Immunodeficiency Virus Coinfected Patients: Performance of Clip™ Sequencing and Line Probe Assay
Naderi et al. Host and Viral Factors Influencing Chronic Hepatitis B Infection Across Three Generations in a Family
Marlet et al. Evolution and phenotypic characterization of whole HBV genome in compliant patients experiencing unexplained entecavir treatment failure
Wei et al. Genetic variation in FCER1A predicts peginterferon alfa‐2a‐induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B
Li et al. Detection of primary YMDD mutations in HBV-related hepatocellular carcinoma using hybridization-fluorescence polarization
CN105648110A (zh) 对治疗性化合物敏感性降低的乙型肝炎变异株、变异株的检测及其用途
Yuan et al. ABCC4, ABCC5 and SLC28A1 polymorphisms: host genome on responses of chronic hepatitis B patients with entecavir treatment
WO2004053162A1 (ja) Ｂ型肝炎ウイルスの薬物抵抗性を識別する方法
JP2017502663A (ja) Ｈｂｖ治療反応に関するバイオマーカー
JP2018500903A (ja) Ｈｂｖ治療反応に関するバイオマーカー
HK40079722A (en) Biomarkers and uses thereof in the treatment of chronic hepatitis b infection
Kim et al. Locked nucleic acid real-time polymerase chain reaction method identifying two polymorphisms of hepatitis B virus genotype C2 infections, rt269L and rt269I

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20190320